Trade Ypsomed Holding AG - YPSN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 3.8 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.015668% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.006555% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | CHF | ||||||||
Margin | 5% | ||||||||
Stock exchange | Switzerland | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Ypsomed Holding AG ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 358.1 |
Open* | 356.6 |
1-Year Change* | 95.61% |
Day's Range* | 350.1 - 359.1 |
52 wk Range | 177.80-309.00 |
Average Volume (10 days) | 8,360.00 |
Average Volume (3 months) | 200.30K |
Market Cap | 4.05B |
P/E Ratio | 55.91 |
Shares Outstanding | 13.65M |
Revenue | 508.61M |
EPS | 5.31 |
Dividend (Yield %) | 0.43771 |
Beta | 1.26 |
Next Earnings Date | May 22, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 28, 2024 | 357.6 | 1.0 | 0.28% | 356.6 | 359.1 | 350.1 |
Mar 27, 2024 | 358.1 | -4.4 | -1.21% | 362.5 | 367.0 | 354.6 |
Mar 26, 2024 | 358.6 | 1.0 | 0.28% | 357.6 | 361.6 | 352.1 |
Mar 25, 2024 | 356.6 | -2.0 | -0.56% | 358.6 | 360.6 | 348.1 |
Mar 22, 2024 | 359.0 | 5.9 | 1.67% | 353.1 | 362.1 | 353.1 |
Mar 21, 2024 | 359.1 | 15.0 | 4.36% | 344.1 | 359.6 | 340.6 |
Mar 20, 2024 | 350.1 | 3.0 | 0.86% | 347.1 | 356.6 | 337.6 |
Mar 19, 2024 | 345.6 | -5.0 | -1.43% | 350.6 | 350.6 | 336.6 |
Mar 18, 2024 | 350.6 | 0.5 | 0.14% | 350.1 | 354.6 | 344.1 |
Mar 15, 2024 | 355.1 | -4.0 | -1.11% | 359.1 | 359.6 | 347.1 |
Mar 14, 2024 | 359.6 | 14.5 | 4.20% | 345.1 | 361.6 | 335.6 |
Mar 13, 2024 | 348.6 | -8.0 | -2.24% | 356.6 | 358.1 | 347.1 |
Mar 12, 2024 | 353.1 | -9.4 | -2.59% | 362.5 | 362.5 | 351.6 |
Mar 11, 2024 | 362.0 | -8.0 | -2.16% | 370.0 | 375.0 | 356.6 |
Mar 8, 2024 | 368.0 | 2.0 | 0.55% | 366.0 | 371.5 | 361.0 |
Mar 7, 2024 | 365.5 | 6.9 | 1.92% | 358.6 | 367.0 | 353.6 |
Mar 6, 2024 | 360.1 | 1.5 | 0.42% | 358.6 | 361.1 | 358.1 |
Mar 5, 2024 | 360.6 | 5.5 | 1.55% | 355.1 | 362.6 | 354.6 |
Mar 4, 2024 | 360.1 | -4.9 | -1.34% | 365.0 | 366.0 | 354.1 |
Mar 1, 2024 | 365.5 | 3.5 | 0.97% | 362.0 | 365.5 | 357.1 |
Ypsomed Holding AG Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, May 22, 2024 | ||
Time (UTC) 10:59 | Country CH
| Event Full Year 2024 Ypsomed Holding AG Earnings Call Full Year 2024 Ypsomed Holding AG Earnings CallForecast -Previous - |
Time (UTC) 10:59 | Country CH
| Event Full Year 2024 Ypsomed Holding AG Earnings Release Full Year 2024 Ypsomed Holding AG Earnings ReleaseForecast -Previous - |
Wednesday, June 26, 2024 | ||
Time (UTC) 10:59 | Country CH
| Event Ypsomed Holding AG Annual Shareholders Meeting Ypsomed Holding AG Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2023 | 2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|---|
Total revenue | 497.46 | 464.841 | 403.656 | 394.264 | 453.765 |
Revenue | 497.46 | 464.841 | 403.656 | 394.264 | 453.765 |
Cost of Revenue, Total | 356.868 | 351.024 | 308.828 | 303.29 | 297.351 |
Gross Profit | 140.592 | 113.817 | 94.828 | 90.974 | 156.414 |
Total Operating Expense | 436.866 | 436.262 | 394.388 | 384.096 | 381.738 |
Selling/General/Admin. Expenses, Total | 103.293 | 89.42 | 94.059 | 89.156 | 90.086 |
Unusual Expense (Income) | -17.394 | -2.8 | -8.181 | 1.317 | |
Other Operating Expenses, Total | -5.901 | -4.182 | -0.699 | -0.169 | -7.016 |
Operating Income | 60.594 | 28.579 | 9.268 | 10.168 | 72.027 |
Interest Income (Expense), Net Non-Operating | -3.736 | -2.904 | -3.104 | -2.432 | -2.608 |
Other, Net | -0.221 | -0.135 | -0.051 | 0.118 | 0.461 |
Net Income Before Taxes | 56.637 | 25.54 | 6.113 | 7.854 | 69.88 |
Net Income After Taxes | 51.275 | 23.105 | 5.811 | 11.734 | 60.136 |
Net Income Before Extra. Items | 51.275 | 23.105 | 5.811 | 11.734 | 60.136 |
Net Income | 51.275 | 23.105 | 5.811 | 11.734 | 60.136 |
Total Adjustments to Net Income | |||||
Income Available to Common Excl. Extra. Items | 51.275 | 23.105 | 5.811 | 11.734 | 60.136 |
Income Available to Common Incl. Extra. Items | 51.275 | 23.105 | 5.811 | 11.734 | 60.136 |
Diluted Net Income | 51.275 | 23.105 | 5.811 | 11.734 | 60.136 |
Diluted Weighted Average Shares | 13.4187 | 12.645 | 12.6122 | 12.603 | 12.603 |
Diluted EPS Excluding Extraordinary Items | 3.82117 | 1.8272 | 0.46074 | 0.93105 | 4.77158 |
Dividends per Share - Common Stock Primary Issue | 1.3 | 0.6 | 1.16 | 0.2 | 0.55 |
Diluted Normalized EPS | 2.64764 | 1.8272 | 0.92805 | 0.50911 | 4.86151 |
Interest Expense (Income) - Net Operating | -5 |
Mar 2023 | Sep 2022 | Mar 2022 | Sep 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total revenue | 253.216 | 244.244 | 242.253 | 222.588 | 204.323 |
Revenue | 253.216 | 244.244 | 242.253 | 222.588 | 204.323 |
Cost of Revenue, Total | 178.072 | 178.796 | 180.778 | 170.246 | 156.813 |
Gross Profit | 75.144 | 65.448 | 61.475 | 52.342 | 47.51 |
Total Operating Expense | 212.068 | 224.798 | 224.162 | 212.1 | 203.397 |
Selling/General/Admin. Expenses, Total | 54.201 | 49.092 | 45.555 | 43.865 | 53.134 |
Unusual Expense (Income) | 0 | ||||
Other Operating Expenses, Total | -20.205 | -3.09 | -2.171 | -2.011 | -6.55 |
Operating Income | 41.148 | 19.446 | 18.091 | 10.488 | 0.926 |
Interest Income (Expense), Net Non-Operating | -1.117 | -2.619 | -0.998 | -1.906 | -2.286 |
Other, Net | -0.133 | -0.088 | -0.12 | -0.015 | -0.157 |
Net Income Before Taxes | 39.898 | 16.739 | 16.973 | 8.567 | -1.517 |
Net Income After Taxes | 35.836 | 15.439 | 15.981 | 7.124 | -0.717 |
Net Income Before Extra. Items | 35.836 | 15.439 | 15.981 | 7.124 | -0.717 |
Net Income | 35.836 | 15.439 | 15.981 | 7.124 | -0.717 |
Income Available to Common Excl. Extra. Items | 35.836 | 15.439 | 15.981 | 7.124 | -0.717 |
Income Available to Common Incl. Extra. Items | 35.836 | 15.439 | 15.981 | 7.124 | -0.717 |
Diluted Net Income | 35.836 | 15.439 | 15.981 | 7.124 | -0.717 |
Diluted Weighted Average Shares | 13.6162 | 13.2212 | 12.6471 | 12.643 | 12.6214 |
Diluted EPS Excluding Extraordinary Items | 2.63187 | 1.16775 | 1.26361 | 0.56348 | -0.05681 |
Dividends per Share - Common Stock Primary Issue | 1.3 | 0 | 0.6 | 0 | 1.16 |
Diluted Normalized EPS | 2.63187 | 1.16775 | 1.26361 | 0.56348 | -0.05681 |
- Annual
- Quarterly
2023 | 2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|---|
Total Current Assets | 208.327 | 193.584 | 185.141 | 189.89 | 178.789 |
Cash and Short Term Investments | 25.224 | 17.038 | 22.411 | 22.334 | 12.083 |
Cash | 25.225 | 17.038 | 19.319 | 13.394 | 12.083 |
Total Receivables, Net | 93.402 | 87.15 | 72.73 | 76.35 | 89.848 |
Accounts Receivable - Trade, Net | 93.336 | 86.986 | 72.663 | 76.29 | 89.695 |
Total Inventory | 57.704 | 68.299 | 63.357 | 56.286 | 52.412 |
Prepaid Expenses | 15.053 | 10.672 | 12.948 | 14.672 | 11.308 |
Other Current Assets, Total | 16.944 | 10.425 | 13.695 | 20.248 | 13.138 |
Total Assets | 861.879 | 756.91 | 717.683 | 678.24 | 587.748 |
Property/Plant/Equipment, Total - Net | 379.587 | 327.945 | 326.197 | 300.712 | 256.142 |
Property/Plant/Equipment, Total - Gross | 733.186 | 647.933 | 624.652 | 572.488 | 500.597 |
Accumulated Depreciation, Total | -353.599 | -319.989 | -298.455 | -271.776 | -244.456 |
Intangibles, Net | 231.738 | 190.779 | 160.728 | 102.516 | 81.419 |
Long Term Investments | 10.729 | 10.847 | 10.85 | 8.57 | 21.225 |
Other Long Term Assets, Total | 31.498 | 33.755 | 34.767 | 33.068 | 2.812 |
Total Current Liabilities | 258.988 | 237.336 | 272.377 | 276.003 | 187.883 |
Accounts Payable | 19.62 | 17.386 | 34.553 | 24.044 | 19.348 |
Accrued Expenses | 44.284 | 36.789 | 29.283 | 26.678 | 31.757 |
Notes Payable/Short Term Debt | 157 | 157 | 182.5 | 182.999 | 112 |
Current Port. of LT Debt/Capital Leases | |||||
Other Current Liabilities, Total | 38.084 | 26.161 | 26.041 | 42.282 | 24.778 |
Total Liabilities | 299.546 | 364.37 | 322.298 | 300.581 | 208.944 |
Total Long Term Debt | 0 | 110 | 32.5 | 10 | 10 |
Long Term Debt | 0 | 110 | 32.5 | 10 | 10 |
Deferred Income Tax | 2.51 | 2.783 | 2.539 | 2.168 | 2.9 |
Other Liabilities, Total | 38.048 | 14.251 | 14.882 | 12.41 | 8.161 |
Total Equity | 562.333 | 392.54 | 395.385 | 377.659 | 378.804 |
Common Stock | 193.144 | 178.994 | 178.994 | 178.994 | 178.994 |
Retained Earnings (Accumulated Deficit) | 708.878 | 559.72 | 551.068 | 547.28 | 539.871 |
Treasury Stock - Common | -0.167 | 0 | -0.956 | -6.595 | -6.595 |
Other Equity, Total | -339.522 | -346.174 | -333.721 | -342.02 | -333.466 |
Total Liabilities & Shareholders’ Equity | 861.879 | 756.91 | 717.683 | 678.24 | 587.748 |
Total Common Shares Outstanding | 13.6487 | 12.6497 | 12.643 | 12.603 | 12.603 |
Note Receivable - Long Term | 0 | 43.484 | 47.361 | ||
Short Term Investments | 0 | 3.091 | 8.94 | ||
Cash & Equivalents | -0.001 | 0.001 |
Sep 2023 | Mar 2023 | Sep 2022 | Mar 2022 | Sep 2021 | |
---|---|---|---|---|---|
Total Current Assets | 249.253 | 208.327 | 192.131 | 193.584 | 185.303 |
Cash and Short Term Investments | 36.379 | 25.224 | 17.15 | 17.038 | 30.047 |
Cash & Equivalents | 36.379 | 25.224 | 17.15 | 17.038 | 27.625 |
Short Term Investments | 0 | 2.422 | |||
Total Receivables, Net | 95.754 | 93.402 | 81.323 | 87.15 | 75.657 |
Accounts Receivable - Trade, Net | 95.691 | 93.336 | 81.264 | 86.986 | 75.59 |
Total Inventory | 69.506 | 57.704 | 70.949 | 68.299 | 62.091 |
Prepaid Expenses | 15.833 | 15.053 | 13.005 | 10.672 | 9.721 |
Other Current Assets, Total | 31.781 | 16.944 | 9.704 | 10.425 | 7.787 |
Total Assets | 936.683 | 861.879 | 790.843 | 756.91 | 734.594 |
Property/Plant/Equipment, Total - Net | 397.764 | 387.677 | 362.447 | 336.15 | 337.179 |
Intangibles, Net | 256.894 | 231.738 | 200.747 | 190.779 | 174.734 |
Long Term Investments | 2.638 | 2.639 | 2.636 | 2.642 | 2.648 |
Note Receivable - Long Term | |||||
Other Long Term Assets, Total | 30.134 | 31.498 | 32.882 | 33.755 | 34.73 |
Total Current Liabilities | 322.278 | 258.988 | 265.15 | 237.336 | 277.833 |
Accounts Payable | 24.599 | 19.62 | 20.701 | 17.386 | 19.762 |
Accrued Expenses | 45.637 | 44.284 | 47.303 | 36.789 | 32.788 |
Notes Payable/Short Term Debt | 203 | 157 | 144 | 157 | 204.5 |
Other Current Liabilities, Total | 49.042 | 38.084 | 28.143 | 26.161 | 20.783 |
Total Liabilities | 362.991 | 299.546 | 281.803 | 364.37 | 350.013 |
Total Long Term Debt | 0 | 0 | 0 | 110 | 55 |
Long Term Debt | 0 | 0 | 110 | 55 | |
Deferred Income Tax | 2.079 | 2.51 | 2.631 | 2.783 | 2.602 |
Other Liabilities, Total | 38.634 | 38.048 | 14.022 | 14.251 | 14.578 |
Total Equity | 573.692 | 562.333 | 509.04 | 392.54 | 384.581 |
Common Stock | 193.144 | 193.144 | 193.144 | 178.994 | 178.994 |
Retained Earnings (Accumulated Deficit) | 727.79 | 708.878 | 672.973 | 559.72 | 543.525 |
Treasury Stock - Common | -0.167 | -0.167 | 0 | -0.956 | |
Other Equity, Total | -347.075 | -339.522 | -357.077 | -346.174 | -336.982 |
Total Liabilities & Shareholders’ Equity | 936.683 | 861.879 | 790.843 | 756.91 | 734.594 |
Total Common Shares Outstanding | 13.6487 | 13.6487 | 13.6497 | 12.6497 | 12.643 |
Current Port. of LT Debt/Capital Leases | 25.003 |
- Annual
- Quarterly
2023 | 2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|---|
Net income/Starting Line | 51.275 | 23.105 | 5.811 | 11.452 | 60.136 |
Cash From Operating Activities | 129.531 | 85.706 | 85.828 | 49.088 | 59.859 |
Cash From Operating Activities | 78.56 | 68.081 | 56.025 | 52.799 | 44.888 |
Non-Cash Items | -11.087 | 1.942 | 36.387 | -29.115 | -44.691 |
Changes in Working Capital | 10.783 | -7.422 | -12.395 | 13.952 | -0.474 |
Cash From Investing Activities | -122.019 | -125.7 | -106.914 | -115.834 | -128.39 |
Capital Expenditures | -169.173 | -127.43 | -126.581 | -118.731 | -129.053 |
Other Investing Cash Flow Items, Total | 47.154 | 1.73 | 19.667 | 2.897 | 0.663 |
Cash From Financing Activities | 1.265 | 38.125 | 26.669 | 68.661 | 49.089 |
Total Cash Dividends Paid | -8.19 | -14.667 | -2.521 | -6.932 | -17.644 |
Issuance (Retirement) of Stock, Net | 34.458 | 0.791 | 6.136 | 0 | -0.005 |
Issuance (Retirement) of Debt, Net | -25.003 | 52 | 22.001 | 71.017 | 63 |
Foreign Exchange Effects | -0.591 | -0.412 | 0.342 | -0.604 | -0.587 |
Net Change in Cash | 8.186 | -2.281 | 5.925 | 1.311 | -20.029 |
Financing Cash Flow Items | 0.001 | 1.053 | 4.576 | 3.738 |
Mar 2023 | Sep 2022 | Mar 2022 | Sep 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | 51.275 | 15.439 | 23.105 | 7.124 | 5.811 |
Cash From Operating Activities | 129.531 | 69.742 | 85.706 | 47.988 | 85.828 |
Cash From Operating Activities | 78.56 | 37.438 | 68.081 | 31.94 | 56.025 |
Non-Cash Items | -11.087 | 1.096 | 1.942 | 0.64 | 36.387 |
Changes in Working Capital | 10.783 | 15.769 | -7.422 | 8.284 | -12.395 |
Cash From Investing Activities | -122.019 | -83.162 | -125.7 | -69.375 | -106.914 |
Capital Expenditures | -169.173 | -83.363 | -127.43 | -68.497 | -126.581 |
Other Investing Cash Flow Items, Total | 47.154 | 0.201 | 1.73 | -0.878 | 19.667 |
Cash From Financing Activities | 1.265 | 13.964 | 38.125 | 29.834 | 26.669 |
Financing Cash Flow Items | 0.001 | 1.053 | |||
Total Cash Dividends Paid | -8.19 | -8.19 | -14.667 | -14.666 | -2.521 |
Issuance (Retirement) of Stock, Net | 34.458 | 35.154 | 0.791 | 6.136 | |
Issuance (Retirement) of Debt, Net | -25.003 | -13 | 52 | 44.5 | 22.001 |
Foreign Exchange Effects | -0.591 | -0.432 | -0.412 | -0.142 | 0.342 |
Net Change in Cash | 8.186 | 0.112 | -2.281 | 8.305 | 5.925 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ypsomed Company profile
About Ypsomed Holding AG
Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.
Financial summary
BRIEF: For the six months ended 30 September 2021, YpsomedHolding AG revenues increased 12% to SF222.6M. Net incomeincreased 7% to SF7.1M. Revenues reflect Diabetes Caresegment increase of 13% to SF95.2M, Delivery Systemssegment increase of 9% to SF118.3M. Net income waspartially offset by Marketing and sales expenses increaseof 7% to SF32.7M (expense), Gains from sale of securitiesdecrease of 98% to SF49K (income).
Equity composition
09/2006, Capital repayment of CHF 1.25 and nominal valuechanged from CHF 11.6. 08/2005, Capital repayment of CHF0.9 & Nominal value changed from CHF 12.5. 06/2009, RightsIssue, 1 new share for every 8 shares held. (Factor: 1.0).07/2009, Nominal value changed from EUR 9.75.
Industry: | Medical Equipment, Supplies & Distribution (NEC) |
Brunnmattstrasse 6
BURGDORF
BERN 3401
CH
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com